discontinued CJC-1295 (DAC) Not FDA-approved Feature Phase III Trial Data Tesamorelin Yes (n=816 pooled) Sermorelin No adult Phase III VAT datasets CJC-1295 (DAC) No Feature Visceral Fat Reduction Tesamorelin 15-20% at 26 weeks Sermorelin Not formally studied in RCTs CJC-1295 (DAC) Not formally studied in RCTs Feature Liver Fat Reduction Tesamorelin 32% at 12 months (NAFLD trial) Sermorelin Not studied CJC-1295 (DAC) Not studied Feature Typical Research Dose Tesamorelin 2 mg daily Sermorelin 200-300 mcg nightly CJC-1295 (DAC) 1-2 mg weekly Feature Unique Advantage Tesamorelin Only FDA-approved GHRH with deepest trial evidence Sermorelin Longest historical track record CJC-1295 (DAC) Weekly dosing convenience Tesamorelin is the only GHRH peptide with active FDA approval and validated Phase III visceral-fat data
When there is sufficient reduced glutathione in the cells, they sacrifice themselves to free radicals to protect cellular mitochondria
Combining Ipamorelin and GHRP-2 Peptides For GH Release The blog explores the synergistic power of combining Ipamorelin and GHRP-2 peptides to enhance growth hormone (GH) release
Youll experience better sleep, improved muscle recovery, more even skin, enhanced immunity, and more
Compound Profiles and Functional Architecture To support rigorous, repeatable analytical trials, the 20mg blend is manufactured to an exact 1:1 quantitative ratio featuring two highly verified research sequences: BPC-157: A synthetic sequence representing the fully functional fragment of human gastric juice protein, optimized for extreme chemical stability in liquid environments and recognized for its extensive cytoprotective properties across soft tissue models
